TABLE 5.

Summary of number of individuals contributing to the MSM‐IPTW and sequential trials analyses and numbers untreated and treated: (A) by year, (B) by visit number.

(A) By year
	MSM‐IPTW			Sequential trials
Year	Number observed	Untreated	Treated	Number observed	Untreated	Treated
2008	1729	1452 (84%)	277 (16%)	1729	1452 (84%)	277 (16%)
2009	537	440 (82%)	97 (18%)	1908	1599 (84%)	309 (16%)
2010	352	285 (81%)	67 (19%)	2004	1637 (82%)	367 (18%)
2011	359	310 (86%)	49 (14%)	2039	1731 (85%)	308 (15%)
2012	264	234 (89%)	30 (11%)	2040	1728 (85%)	312 (15%)
2013	179	156 (87%)	23 (13%)	1916	1652 (86%)	264 (14%)
2014	152	127 (84%)	25 (16%)	1866	1601 (86%)	265 (14%)
2015	123	100 (81%)	23 (19%)	1779	1519 (85%)	260 (15%)
2016	90	79 (88%)	11 (12%)	1629	1426 (88%)	203 (12%)
2017	70	60 (86%)	10 (14%)	1529	1325 (87%)	204 (13%)

(B) By visit number $k$
	MSM‐IPTW				Sequential trials
Visit	Number observed	Untreated	Treated		Number observed	Untreated	Treated
0	3855	3243 (84%)	612 (16%)		18439	15670 (85%)	2769 (15%)
1	3466	2901 (84%)	565 (16%)		16889	14321 (85%)	2568 (15%)
2	3121	2609 (84%)	512 (16%)		12302	10347 (84%)	1955 (16%)
3	2821	2350 (83%)	471 (17%)		8958	7408 (83%)	1550 (17%)
4	2500	2101 (84%)	399 (16%)		6308	5196 (82%)	1112 (18%)
5	2205	1851 (84%)	354 (16%)		4380	3564 (81%)	816 (19%)
6	1870	1565 (84%)	305 (16%)		2929	2335 (80%)	594 (20%)
7	1570	1308 (83%)	262 (17%)		1899	1490 (78%)	409 (22%)
8	1246	1036 (83%)	210 (17%)		1154	882 (76%)	272 (24%)
9	972	824 (85%)	148 (15%)		609	472 (78%)	137 (22%)
10	643	548 (85%)	95 (15%)		241	187 (78%)	54 (22%)